Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 206
- Press Release
- Press Release PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403
- (주)파멥신
- 18 Dec 2025
- Views822
- 0
- 205
- Press Release
- Press Release PharmAbcine’s PMC-309 successfully passed Safety Review Committee for 2mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors
- (주)파멥신
- 21 Aug 2025
- Views2735
- 0
- 204
- News Article
- News Article PharmAbcine to Present PMC-403 and Vascular Normalization Platform at BIO USA 2025_THE BIO
- (주)파멥신
- 9 Jun 2025
- Views3398
- 0
- 203
- Press Release
- Press Release PharmAbcine’s PMC-309 successfully completes 1mg/kg Cohort in Phase 1 Trial for Advanced or Metastatic Solid Tumors
- (주)파멥신
- 19 May 2025
- Views3722
- 0
- 202
- News Article
- News Article PharmAbcine and Arontier Partnership for AI-Driven Antibody-Based Drug Development Platform_THE BIO
- (주)파멥신
- 12 Feb 2025
- Views4812
- 0
- 201
- Press Release
- Press Release PharmAbcine at JP Morgan Healthcare Conference 2025
- (주)파멥신
- 10 Jan 2025
- Views4857
- 0
- 200
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 3mg Multiple-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- (주)파멥신
- 9 Jan 2025
- Views4178
- 0
- 199
- Press Release
- Press Release PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration
- PharmAbcine
- 16 Oct 2024
- Views4451
- 0
